Price
No data yet.
Social Signal Score
Analyst Ratings
39 analystsRevenue
$254.56M+1970.77%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John F. Sheridan
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 2,500
- Beta
- 1.56
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 0.42
Financials
Revenue
$254.56M+1970.8%Net Income
$-21.17MEBITDA
$-9.23MFree Cash Flow
$-38.68MEPS (diluted)
$-0.31Shares Outstanding (diluted)
68.40M+2133.0%Operating Expenses
$158.57MCash & Debt
$456.00MReturn of Capital
$0.00Revenue by Segment (annual)
$1.01BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.01B | $-204.71M | $-3.04 |
| 2024 | $940.20M | $-96.03M | $-1.47 |
| 2023 | $747.72M | $-222.61M | $-3.43 |
| 2022 | $801.22M | $-94.59M | $-1.47 |
| 2021 | $702.80M | $15.57M | $0.25 |
| 2020 | $498.83M | $-34.38M | $-0.56 |
| 2019 | $362.31M | $-24.75M | $-0.42 |
| 2018 | $183.87M | $-122.61M | $-2.55 |
| 2017 | $107.60M | $-73.03M | $-12.86 |
| 2016 | $84.25M | $-83.45M | $-27.30 |
| 2015 | $72.85M | $-72.42M | $-25.04 |
| 2014 | $49.72M | $-79.52M | $-34.17 |
| 2013 | $29.01M | $-63.14M | $-27.53 |
| 2012 | $2.47M | $-33.02M | $-26.32 |
Valuation
TNDMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+7.14%Social Signal Score
Mentions (5)
- Newsbusinesswire.com·8d ago·Neutral
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
View source ↗ - Newszacks.com·19d ago·Neutral
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock? Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
View source ↗ - Newszacks.com·26d ago·Positive
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
View source ↗ - Newsbenzinga.com·45d ago·Positive
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
View source ↗ - Newszacks.com·55d ago·Neutral
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $-0.27 per share
Typical surprise +3.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.31 vs $-0.32beat
- Thu, May 7$-0.30 vs $-0.46beat
- Thu, Feb 19$-0.01 vs $-0.05beat
- Thu, Nov 6$-0.31 vs $-0.31beat
- Wed, Aug 6$-0.48 vs $-0.40miss
- Wed, Apr 30$-0.67 vs $-0.60miss
Estimates and results for TNDM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by TNDM officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 8, 2026 (36d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Oct 16, 2025 (24d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Apr 11, 2025 (23d later)Sell$1,001 - $15,000
- Gilbert Ray Cisneroshouse · CA31 · disclosed Apr 7, 2025 (34d later)Buy$1,001 - $15,000
- Josh S. Gottheimerhouse · NJ05 · disclosed Sep 11, 2024 (37d later)Buy$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (32d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 8, 2022 (16d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Jun 10, 2022 (18d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.